Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.
In ulcerative colitis (UC), Lilly’s Omvoh has taken the lead as the first approved anti-IL-23p19 inhibitor (2023). Lilly’s emphasis on patient-reported outcomes (PROs) has differentiated Omvoh ...
Omvoh is now approved in the U.S. for two types ... class treatment for moderately to severely active ulcerative colitis (UC) in adults.1 Eli Lilly and Company (NYSE: LLY) today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback